| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Basic Study |
| Article Title |
γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Charupong Saengboonmee, Supannika Sorin, Sakkarn Sangkhamanon, Surang Chomphoo, Somsiri Indramanee, Wunchana Seubwai, Kanyarat Thithuan, Ching-Feng Chiu, Seiji Okada, Marie-Claude Gingras and Sopit Wongkham |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Research Grant for Young Talented Scholars, National Research Council of Thailand |
N41A640108 |
|
| Corresponding Author |
Charupong Saengboonmee, MD, PhD, Doctor, Lecturer, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, 123 Mitraphap Highway, Khon Kaen 40002, Thailand. charusa@kku.ac.th |
| Key Words |
Baclofen; Cholangiocarcinoma; Diabetes mellitus; Drug repurposing; Hyperglycemia; Gamma-aminobutyric acid |
| Core Tip |
Diabetes mellitus (DM) is associated with an increased risk and progression of cholangiocarcinoma (CCA). The γ-aminobutyric acid (GABA) B2 receptor (GABBR2) was upregulated in CCA cells cultured in high glucose and in CCA tissues from patients with hyperglycemia. High GABBR2 expressions were significantly correlated with a non-papillary histotype and smaller sizes of CCA tumors. The treatment of baclofen, a GABA-B receptor agonist, significantly suppressed CCA cell proliferation and clonogenicity, suggesting that GABBR2 is a potential target for CCA treatment. Baclofen inhibited multiple kinases and signal transducers in CCA, resulting in downregulated downstream target proteins involving cell proliferation and suppression of CCA cell growth. |
| Publish Date |
2023-07-26 11:55 |
| Citation |
Saengboonmee C, Sorin S, Sangkhamanon S, Chomphoo S, Indramanee S, Seubwai W, Thithuan K, Chiu CF, Okada S, Gingras MC, Wongkham S. γ-aminobutyric acid B2 receptor: A potential therapeutic target for cholangiocarcinoma in patients with diabetes mellitus. World J Gastroenterol 2023; 29(28): 4416-4432 |
| URL |
https://www.wjgnet.com/1007-9327/full/v29/i28/4416.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v29.i28.4416 |
